National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

Statutory Rules

1980 No. 69

REGULATIONS UNDER THE NATIONAL HEALTH ACT 19531

WHEREAS it is provided by sub-section 101 (4) of the National Health Act 1953 that a drug or medicinal preparation that was not a pharmaceutical benefit under that Act immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

 

AND WHEREAS that Committee has recommended to the Minister that the following drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953, namely the drugs and medicinal preparations specified in Schedule 3 to the National Health (Pharmaceutical Benefits) Regulations, as amended by the following Regulations, that had not previously been prescribed as pharmaceutical benefits:

 

 NOW THEREFORE I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953.

 Dated this twenty-seventh day of March 1980.

 ZELMAN COWEN

 Governor-General

 By His Excellency’s Command,

MICHAEL MACKELLAR

Minister of State for Health

_______________

AMENDMENTS OF THE NATIONAL HEALTH

(PHARMACEUTICAL BENEFITS) REGULATIONS2

1Commencement

 These Regulations shall come into operation on 1 April 1980.

2Schedule 1

 Schedule 1 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 1.

3Schedule 2

 Schedule 2 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 2.

4Schedule 3

 Schedule 3 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 3.

5Schedule 5

 Schedule 5 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 4.

_______________

SCHEDULE 1

Regulation 2

AMENDMENTS OF SCHEDULE 1 TO THE NATIONAL HEALTH (PHARMACEUTICAL (PHARMACEUTICAL BENEFITS) REGULATIONS

• 1.

  After Item 49 insert the following item:

“49A Belladonna Herb, Prepared”.

• 2.

  After Item 108 insert the following item:

“108A Chloroquine Phosphate”.

• 3.

  After Item 257 insert the following item:

“257A Ethopropazine Tablets”.

• 4.

  After Item 373 insert the following item:

“373A Lanatoside C”.

• 5.

  After Item 411 insert the following item:

“411A Meclozine Hydrochloride”.

• 6.

  After Item 518 insert the following item:

“518A Pancreatin”.

• 7.

  After Item 539 insert the following item:

“539A Pertussis Vaccine”.

_______________

SCHEDULE 2

Regulation 3

AMENDMENTS OF SCHEDULE 2 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

• 1.

  Omit Item 10.

• 2.

  Omit Item 11.

• 3.

  Omit Item 13.

• 4.

  Omit Item 14.

• 5.

  After Item 56 insert the following items:

“56A	Chlortetracycline	—”.
“56B	Chlortetracycline Hydrochloride	—”.

• 6.

  Omit Item 89, substitute the following item:

“89 Ergotamine Tartrate Caffeine Citrate with Diphenhydramine Hydrochloride and Ergotamine Tartrate Caffeine with Cyclizine Hydrochloride and Ergotamine Tartrate Caffeine with Ergotamine Tartrate”.

• 7.

  Omit Item 110, substitute the following item:

“110 Glucose and Ketone Indicator—Urine —”.

• 8.

  Omit Item 117.

• 9.

  Omit Item 120, substitute the following item:

“120 Hydrocortisone Acetate Neomycin Sulphate with Hydrocortisone Acetate”.

• 10.

  Omit Item 121, substitute the following items:

“121	Hyoscine Hydrobromide, B.P.	Atropine Sulphate, B.P. with Hyoscyamine Hydrobromide, B.P. and Hyoscine Hydrobromide, B.P. Atropine Sulphate, B.P. with Hyoscyamine Sulphate and Hyoscine Hydrobromide, B.P. Papaveretum with Hyoscine Hydrobromide, B.P.
“121A	Hyoscyamine Hydrobromide	Atropine Sulphate, B.P. with Hyoscine Hydrobromide, B.P. and Hyoscyamine Hydrobromide”.

• 11.

  Omit Item 140.

• 12.

  Omit Item 161, substitute the following item:

“161 Oxytetracycline Hydrochloride, B.P. —”.

• 13.

  Omit Item 163.

• 14.

  Omit Item 177, substitute the following item:

“177 Polymyxin B Sulphate Bacitracin with Neomycin Sulphate and Polymyxin B Sulphate Bacitracin Zinc with Neomycin Sulphate and Polymyxin B Sulphate Chloramphenicol with Polymyxin B Sulphate Neomycin Sulphate with Gramicidin and Polymyxin B Sulphate Neomycin Sulphate with Hydrocortisone and Polymyxin B Sulphate Propylene Glycol with Acetic Acid and Polymyxin B Sulphate”.

• 15.

  Omit Item 188.

_______________

SCHEDULE 3

Regulation 4

AMENDMENTS OF SCHEDULE 3 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

• 1.

  Omit Item 21.

• 2.

  Omit Item 22.

• 3.

  Omit Item 24.

• 4.

  Omit Item 25.

• 5.

  After Item 76 insert the following item:

“76A Chlortetracycline”.

• 6.

  Omit Item 138, substitute the following item:

“138 Glucose and Ketone Indicator—Urine”.

• 7.

  After Item 154 insert the following item:

“154A Hyoscyamine Hydrobromide”.

• 8.

  Omit Item 267.

_______________

SCHEDULE 4

Regulation 5

AMENDMENTS OF SCHEDULE 5 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

• 1.

  Omit Item 36, substitute the following items:

“36	Chlormethiazole	With the written authority of the Permanent Head— Short-term hospital use for alcohol or drug withdrawal therapy Status epilepticus
“36A	Chlormethiazole Edisylate	Short-term hospital use for alcohol or drug withdrawal therapy Status epilepticus”.

• 2.

  Omit Item 52, substitute the following item:

“52 Danazol With the written authority of the Permanent Head— Endometriosis proven by laparoscopy or laparotomy Hereditary angio-oedema”.

• 3.

  Omit Item 91, substitute the following item:

“91 Influenza Vaccine Prophylaxis of persons at special risk of adverse consequences from infections of the lower respiratory tract”.

• 4.

  Omit Item 108, substitute the following item:

“108 (1) Methadone Injection, B.P. (2) Methadone Tablets, B.P Disabling pain associated with proven malignant neoplasia Disabling pain associated with self-limiting disorders of short duration not responding to non-narcotic analgesics, the maximum duration of treatment being two weeks”.

• 5.

  Omit Item 136, substitute the following item:

“136	(1) Pancreatin Enzyme 4X U.S.N.F. XIII strength	Cystic fibrosis (mucoviscidosis) Following pancreatico-duodenectomy
(2) Pancreatin Enzyme 5X U.S.N.F. XIV strength	Pancreatic steatorrhoea”.
(3) Pancrelipase

• 6.

  Omit Item 138, substitute the following item:

“138 Pentazocine Lactate Injection, B.P Disabling pain associated with proven malignant neoplasia Disabling pain associated with self-limiting disorders of short duration not responding to non-narcotic analgesics, the maximum duration of treatment being two weeks”.

• 7.

  After Item 161 insert the following item:

“161A Pyrimethamine, B.P. with Sulfadoxine Prophylaxis or treatment of chloroquine-resistant falciparum malaria only”.

• 8.

  Omit Item 190, substitute the following items:

“190	Verapamil Hydrochloride Injection	Cardiac arrhythmias
“190A	Verapamil Hydrochloride Tablets	With the written authority of the Permanent Head— Angina at rest (Prinzmetal) in patients who are not taking a beta blocking drug Angina associated with respiratory disease in patients who are not taking a beta blocking drug Cardiac arrhythmias in patients who are not taking a beta blocking drug”.

 

NOTES

1. Notified in the Commonwealth of Australia Gazette on 31 March 1980.

2. Statutory Rules 1960 No. 17 as amended by Statutory Rules 1960 Nos. 90 and 102; 1961 Nos. 59 and 137; 1962 Nos. 34, 101 and 114; 1963 Nos. 34, 69 and 107; 1964 Nos. 12, 57 and 135; 1965 Nos. 51, 151 and 152; 1966 Nos. 80 and 144; 1967 Nos. 67, 116 and 158; 1968 Nos. 44, 76, 88 and 146; 1969 Nos. 44, 107 and 185; 1970 Nos. 39, 94, 119 and 186; 1971 Nos. 44, 101, 136 and 154; 1972 Nos. 32, 121 and 205; 1973 Nos. 15, 57, 139 and 229; 1974 Nos. 37, 126 and 222; 1975 Nos. 50, 148 and 209; 1976 Nos. 84, 150, 195 and 255; 1977 Nos. 39, 125 and 221; 1978 Nos. 47, 142, 153 and 245; 1979 Nos. 51, 55, 144 and 250.